Therapeutic options for refractory gastroesophageal reflux disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue SUPPL.3, 2012, Pages 3-7

  Fass, Ronnie ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Gastroesophageal reflux disease (GERD); Heartburn; Proton pump inhibitors (PPIs); Refractory GERD

Indexed keywords

ADX 10059; ANALGESIC AGENT; ARBACLOFEN PLACARBIL; BACLOFEN; BOTULINUM TOXIN; COLESTYRAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ACUPUNCTURE; ALTERNATIVE MEDICINE; ANTIREFLUX OPERATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; DRUG TREATMENT FAILURE; ESOPHAGOSCOPY; ESOPHAGUS MOTILITY; ESOPHAGUS PAIN; GASTROESOPHAGEAL REFLUX; HIATUS HERNIA; HUMAN; LIFESTYLE MODIFICATION; LIVER FAILURE; LIVER FUNCTION TEST; LOWER ESOPHAGUS SPHINCTER; PRIORITY JOURNAL; PSYCHOTHERAPY; REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE; REVIEW; SIDE EFFECT; STOMACH PARESIS; SUCTION; UNSPECIFIED SIDE EFFECT; VISCERAL PAIN;

EID: 84859407553     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07064.x     Document Type: Review

References (53)

1. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56.
2. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am. J. Dig. Dis. 1976; 21: 953-6.
3. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
4. Hershcovici T, Fass R. Nonerosive reflux disease (NERD)-an update. J. Neurogastroenterol. Motil. 2010; 16: 8-21.
5. Hershcovici T, Fass R. Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors. Curr. Opin. Gastroenterol. 2010; 26: 367-78.
6. Hershcovici T, Fass R. An algorithm for diagnosis and treatment of refractory GERD. Best Pract. Res. Clin. Gastroenterol. 2010; 24: 923-36.
7. Fass R. Proton pump inhibitor failure-what are the therapeutic options? Am. J. Gastroenterol. 2009; 104 (Suppl. 2): S33-8.
8. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009; 58: 295-309.
9. Fass R, Gasiorowska A. Refractory GERD: what is it? Curr. Gastroenterol. Rep. 2008; 10: 252-7.
10. Fass R. Persistent heartburn in a patient on proton-pump inhibitor. Clin. Gastroenterol. Hepatol. 2008; 6: 393-400.
11. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch. Intern. Med. 2006; 166: 965-71.
12. Pomiecinski F, Yang AC, Navarro-Rodrigues T, Kalil J, Castro FF. Sensitization to foods in gastroesophageal reflux disease and its relation to eosinophils in the esophagus: is it of clinical importance? Ann. Allergy Asthma Immunol. 2010; 105: 359-63.
13. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115: 1335-9.
14. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122: 625-32.
15. Mainie I, Tutuian R, Castell DO. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. J. Clin. Gastroenterol. 2008; 42: 676-9.
16. Rackoff A, Agrawal A, Hila A, Mainie I, Tutuian R, Castell DO. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis. Esophagus 2005; 18: 370-3.
17. Kahrilas PJ, Shaheen NJ, Vaezi MF etal. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1383-91, 91 e1-5.
18. Fass R, Sontag SJ, Traxler B, Sostek M. Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin. Gastroenterol. Hepatol. 2006; 4: 40-56.
19. Moayyedi P, Armstrong D, Hunt RH, Lei Y, Bukoski M, White RJ. The gain in quality-adjusted life months by switching to esomeprazole in those with continued reflux symptoms in primary care: encomPASS-a cluster-randomized trial. Am. J. Gastroenterol. 2010; 105: 2341-6.
20. Hatlebakk J, Katz P, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40mg daily. Aliment. Pharmacol. Ther. 1998; 12: 1235-40.
21. Frazzoni M, Manno M, De Micheli E, Savarino V. Efficacy in intra-oesophageal acid suppression may decrease after 2-year continuous treatment with proton pump inhibitors. Dig. Liver Dis. 2007; 39: 415-21.
22. Shimatani T, Moriwaki M, Xu J, Tazuma S, Inoue M. Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers. Dig. Liver Dis. 2006; 38: 802-8.
23. Sharma P, Shaheen NJ, Perez MC etal. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation-results from two randomized controlled studies. Aliment. Pharmacol. Ther. 2009; 29: 731-41.
24. Fass R, Chey WD, Zakko SF etal. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment. Pharmacol. Ther. 2009; 29: 1261-72.
25. Blackshaw LA. Receptors and transmission in the brain-gut axis: potential for novel therapies. IV. GABA(B) receptors in the brain-gastroesophageal axis. Am. J. Physiol. Heart Circ. Physiol. 2001; 281: G311-15.
26. Frisby CL, Mattsson JP, Jensen JM, Lehmann A, Dent J, Blackshaw LA. Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology 2005; 129: 995-1004.
27. Zhang Q, Lehmann A, Ridga R, Dent J, Holloway RH. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 2002; 50: 19-24.
28. Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 2000; 118: 7-13.
29. Omari TI, Benninga MA, Sansom L, Butler RN, Dent J, Davidson GP. Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. J. Pediatr. 2006; 149: 436-8.
30. Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment. Pharmacol. Ther. 2003; 17: 243-51.
31. Koek GH, Sifrim D, Lerut T, Janssens J, Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003; 52: 1397-402.
32. Liu LS, Shenoy M, Pasricha PJ. The analgesic effects of the GABA(B) receptor agonist, baclofen, in a rodent model of functional dyspepsia. Neurogastroenterol. Motil. 2011; 23: 356-61.
33. Lal R, Sukbuntherng J, Tai EH etal. Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. J. Pharmacol. Exp. Ther. 2009; 330: 911-21.
34. Gerson LB, Huff FJ, Hila A etal. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am. J. Gastroenterol. 2010; 1266-75.
35. Boeckxstaens GE, Beaumont H, Mertens V etal. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 2010; 139: 409-17.
36. Boeckxstaens GE, Beaumont H, Hatlebakk JG, Silberg DG, Adler J, Denison H. Efficacy and tolerability of the novel reflux inhibitor, AZD3355, As add-on treatment in GERD patients with symptoms despite proton pump inhibitor therapy. Gastroenterology 2009; 136: A436-A.
37. Keywood C, Wakefield M, Tack J. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 2009; 58: 1192-9.
38. Zerbib F, Bruley des Varannes S, Roman S etal. Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 2011; 33: 911-21.
39. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next? Aliment. Pharmacol. Ther. 2005; 22: 79-94.
40. Mainie I, Tutuian R, Shay S etal. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006; 55: 1398-402.
41. Handa M, Mine K, Yamamoto H etal. Antidepressant treatment of patients with diffuse esophageal spasm: a psychosomatic approach. J. Clin. Gastroenterol. 1999; 28: 228-32.
42. Clouse RE, Lustman PJ, Eckert TC, Ferney DM, Griffith LS. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology 1987; 92: 1027-36.
43. Mirbagheri SA, Sadeghi A, Amouie M etal. Pyloric injection of botulinum toxin for the treatment of refractory GERD accompanied with gastroparesis: a preliminary report. Dig. Dis. Sci. 2008; 53: 2621-6.
44. Bromer MQ, Friedenberg F, Miller LS, Fisher RS, Swartz K, Parkman HP. Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest. Endosc. 2005; 61: 833-9.
45. Rosenthal R, Peterli R, Guenin MO, van Flüe M, Ackermann C. Laparoscopic antireflux surgery: long-term outcomes and quality of life. J. Laparoendosc. Adv. Surg. Tech. A 2006; 16: 557-61.
46. Becker V, Bajbouj M, Waller K, Schmid RM, Meining A. Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors-a follow-up study of intraluminal-impedance guided therapy. Aliment. Pharmacol. Ther. 2007; 26: 1355-60.
47. del Genio G, Tolone S, del Genio F etal. Prospective assessment of patient selection for antireflux surgery by combined multichannel intraluminal impedance pH monitoring. J. Gastrointest. Surg. 2008; 12: 1491-6.
48. Mainie I, Tutuian R, Agrawal A, Adams D, Castell DO. Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. Br. J. Surg. 2006; 93: 1483-7.
49. Frazzoni M, Conigliaro R, Melotti G. Reflux parameters as modified by laparoscopic fundoplication in 40 patients with heartburn/regurgitation persisting despite PPI therapy: a study using impedance-pH monitoring. Dig. Dis. Sci. 2011; 56: 1099-106.
50. Cadiere GB, Buset M, Muls V etal. Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study. World J. Surg. 2008; 32: 1676-88.
51. Dickman R, Schiff E, Holland A etal. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment. Pharmacol. Ther. 2007; 26: 1333-44.
52. Rubenstein JH, Nojkov B, Korsnes S etal. Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment. Pharmacol. Ther. 2007; 26: 443-53.
53. Nojkov B, Rubenstein JH, Adlis SA etal. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 2008; 27: 473-82.